Loading
A phase 2 trial of Osimertinib and Savolitinib in advanced solid tumours, run by AstraZeneca, active and no longer recruiting.
Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib is a phase 2 interventional study registered as NCT03778229 by AstraZeneca, with 367 participants enrolled, started 2019-01-09 and due to reach its primary completion in 2024-08-23. Interventions recorded: osimertinib, savolitinib and placebo. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
367 enrolled.
95% CI 44.70 to 67.32; Figures from the ClinicalTrials.gov results section (first posted 2026-02-10), not from a publication
Source95% CI 25.19 to 38.64; Figures from the ClinicalTrials.gov results section (first posted 2026-02-10), not from a publication
Source95% CI 11.89 to 17.87; Figures from the ClinicalTrials.gov results section (first posted 2026-02-10), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Objective Response Rate (ORR) by Investigator Assessment; Target Population Analysis Setprimary | Savo 300 mg BID + Osi | 80 | 56.3% | - | - | link |
| Objective Response Rate (ORR) by Investigator Assessment; 300 mg QD Safety Analysis Setprimary | Savo 300 mg QD + Osi | 196 | 31.6% | - | - | link |
| Overall Survival (OS); Target Population Analysis Set | Savo 300 mg BID + Osi | 80 | 14.42 months | - | - | link |
Shares Savolitinib, MET exon 14 and MET-amplified non-small-cell lung cancer, Osimertinib, EGFR-mutated non-small-cell lung cancer and the tag pipeline.
Shares Savolitinib, AstraZeneca, Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Shares Osimertinib, AstraZeneca, Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Shares Savolitinib, Hutchmed, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Osimertinib, AstraZeneca, Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Shares Osimertinib, AstraZeneca, Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Osimertinib, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.